Prolucent Receives Strategic Investment from Northwell Holdings to Enhance Healthcare Workforce Management
Prolucent®, a leading provider of healthcare workforce optimization software and services, has announced a strategic investment from Northwell Holdings, the for-profit investment arm of Northwell Health, New York’s largest healthcare…
Glaukos Reports Positive Phase 3 Results for Epioxa™, Meeting Primary Efficacy Endpoint
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced positive results from the second Phase…
Caracal and I2Pure Team Up to Launch New Disinfection Products
Caracal Products & Services and I2Pure have announced a collaboration to introduce new cutting-edge disinfection and antimicrobial products. Caracal, a certified Minority Business Enterprise and Tier 1 diversity spend supplier,…
PursueCare Launches FDA-Authorized RESET® and RESET-O® for Addiction Treatment
PursueCare, a leader in virtual addiction treatment, has announced the launch of RESET® and RESET-O®, the first FDA-authorized prescription digital therapeutics for substance use disorder (SUD) and opioid use disorder…
Acadia Pharmaceuticals Gets Health Canada Approval for DAYBUE™ in Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that Health Canada has granted marketing authorization for DAYBUE™ (trofinetide) to treat Rett syndrome in patients aged two and older. This approval, under…
bit.bio Secures Landmark Patent Defense for opti-ox™ Cell Programming Technology
bit.bio, a leader in synthetic biology focused on coding human cells for innovative therapies, has successfully defended its foundational European patent for opti-ox. This groundbreaking technology allows for the deterministic…
Celltrion Reveals Two-Year Post-Hoc Analysis Results for Subcutaneous Infliximab (CT-P13 SC) in IBD Treatment
Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the…
FDA Approves Novocure’s Optune Lua® for Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) has announced that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for use alongside PD-1/PD-L1 inhibitors or docetaxel. This treatment is intended for adult…
Simple Blood Test Can Predict Future Heart Attacks and Cardiac Events
Siemens Healthineers has announced a new prognostic claim for its Atellica IM High-Sensitivity Troponin I (TnIH) test, significantly enhancing care for at-risk cardiac patients in the U.S. This straightforward blood…
Airway Therapeutics Launches Phase 3 Study of Zelpultide Alfa for Preterm Infants at Risk of BPD
Airway Therapeutics, Inc. has announced the launch of a multinational Phase 3 clinical trial for zelpultide alfa (rhSP-D). This study aims to prevent bronchopulmonary dysplasia (BPD) and mitigate lung injury…
Invisalign® Palatal Expander Now Available in Hong Kong for Dental Growth
Align Technology, Inc. (Nasdaq: ALGN), a global leader in medical devices known for its Invisalign® clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, has announced the launch of its…
MEDiC Life Sciences Secures $5M Investment from LG and Hanmi for Cancer Biomarker Technology
MEDiC Life Sciences, a prominent functional genomics startup in Silicon Valley, has announced a $5M strategic investment from LG and Hanmi Pharmaceutical. This funding precedes MEDiC’s upcoming Series-A round later…